# Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

> **NCT05531708** · PHASE1 · WITHDRAWN · sponsor: **Shanghai Pudong Hospital**

## Conditions studied

- Mesothelin-positive Advanced Refractory Solid Tumors

## Interventions

- **BIOLOGICAL:** Anti-mesothelin CAR-T cells
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT05531708
- **Lead sponsor:** Shanghai Pudong Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-04-02
- **Primary completion:** 2025-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study is not initiated and we want it to be withdrawn.
- **Last updated:** 2023-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05531708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05531708, "Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05531708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*